{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:22:04Z","timestamp":1778649724379,"version":"3.51.4"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"am","delay-in-days":507,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.semnephrol.2022.01.003","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T06:23:19Z","timestamp":1653286999000},"page":"63-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging Concepts in Managing Malignancy in Kidney Transplant Patients"],"prefix":"10.1016","volume":"42","author":[{"given":"Brittany","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala","family":"Abudayyeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoka","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl s1","key":"10.1016\/j.semnephrol.2022.01.003_bib0001","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ajt.15672","article-title":"OPTN\/SRTR 2018 annual data report: kidney","volume":"20","author":"Hart","year":"2020","journal-title":"Am J Transplant."},{"issue":"21","key":"10.1016\/j.semnephrol.2022.01.003_bib0002","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1001\/jama.294.21.2726","article-title":"Deceased-donor characteristics and the survival benefit of kidney transplantation","volume":"294","author":"Merion","year":"2005","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0003","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1681\/ASN.2005090984","article-title":"Acute myocardial infarction and kidney transplantation","volume":"17","author":"Kasiske","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2022.01.003_bib0004","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1111\/j.1600-6143.2011.03691.x","article-title":"Change in mortality risk over time in young kidney transplant recipients","volume":"11","author":"Foster","year":"2011","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0005","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.kint.2020.10.018","article-title":"Changes in cancer incidence and outcomes among kidney transplant recipients in the United States over a thirty-year period","volume":"99","author":"Blosser","year":"2021","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0006","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1681\/ASN.2020050566","article-title":"Death after kidney transplantation: an analysis by era and time post-transplant","volume":"31","author":"Ying","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.semnephrol.2022.01.003_bib0007","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.semnephrol.2022.01.003_bib0008","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41581-018-0022-6","article-title":"Cancer in kidney transplant recipients","volume":"14","author":"Au","year":"2018","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0009","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2007.01908.x","article-title":"Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients","volume":"7","author":"Webster","year":"2007","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2022.01.003_bib0010","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1111\/ajt.13818","article-title":"Comparison of cancer diagnoses between the US Solid Organ Transplant Registry and Linked Central Cancer Registries","volume":"16","author":"Yanik","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0011","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1681\/ASN.2018090906","article-title":"Overall and site-specific cancer mortality in patients on dialysis and after kidney transplant","volume":"30","author":"Au","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0012","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jamaoncol.2015.5137","article-title":"Cancer mortality among recipients of solid-organ transplantation in Ontario","volume":"2","author":"Acuna","year":"2016","journal-title":"Canada. JAMA Oncol."},{"issue":"9581","key":"10.1016\/j.semnephrol.2022.01.003_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semnephrol.2022.01.003_bib0014","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1600-6143.2009.02728.x","article-title":"Cancer mortality in kidney transplantation","volume":"9","author":"Kiberd","year":"2009","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/cncr.31782","article-title":"Survival after a cancer diagnosis among solid organ transplant recipients in the United States","volume":"125","author":"D'Arcy","year":"2019","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0016","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-6143.2007.01736.x","article-title":"Cancer incidence among Canadian kidney transplant recipients","volume":"7","author":"Villeneuve","year":"2007","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0017","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/TP.0b013e3181ff1458","article-title":"Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study","volume":"90","author":"van de Wetering","year":"2010","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0018","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/TP.0b013e3181a238f6","article-title":"De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population","volume":"87","author":"Miao","year":"2009","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.semnephrol.2022.01.003_bib0019","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S1470-2045(07)70315-7","article-title":"Management of solid tumours in organ-transplant recipients","volume":"8","author":"Ajithkumar","year":"2007","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0020","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"10.1016\/j.semnephrol.2022.01.003_bib0021","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/cncr.32136","article-title":"Cancer-attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014","volume":"125","author":"Noone","year":"2019","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0022","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/cncr.28043","article-title":"Cumulative incidence of cancer after solid organ transplantation","volume":"119","author":"Hall","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0023","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1002\/cncr.29324","article-title":"Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients","volume":"121","author":"Shiels","year":"2015","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0024","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1111\/ajt.15495","article-title":"Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer","volume":"19","author":"Engels","year":"2019","journal-title":"Am J Transplant"},{"issue":"4S1 suppl 1","key":"10.1016\/j.semnephrol.2022.01.003_bib0025","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/TP.0000000000003136","article-title":"KDIGO Clinical Practice Guideline on the evaluation and management of candidates for kidney transplantation","volume":"104","author":"Chadban","year":"2020","journal-title":"Transplantation"},{"issue":"suppl 2","key":"10.1016\/j.semnephrol.2022.01.003_bib0026","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.2215\/CJN.03320807","article-title":"Cancer screening in renal transplant recipients: what is the evidence?","volume":"3","author":"Wong","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.semnephrol.2022.01.003_bib0027","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/TP.0000000000002178","article-title":"Solid organ transplantation in patients with preexisting malignancies in remission: a propensity score matched cohort study","volume":"102","author":"Acuna","year":"2018","journal-title":"Transplantation."},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0028","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/TP.0b013e31829854b7","article-title":"Wilczek HE. Overall and cause-specific mortality in transplant recipients with a pretransplantation cancer history","volume":"96","author":"Brattstr\u00f6m","year":"2013","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0029","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/TP.0000000000001192","article-title":"Outcomes of solid organ transplant recipients with preexisting malignancies in remission: a systematic review and meta-analysis","volume":"101","author":"Acuna","year":"2017","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0030","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jamcollsurg.2019.06.001","article-title":"Impact of pre-transplant malignancy on outcomes after kidney transplantation: United Network for Organ Sharing database analysis","volume":"229","author":"Livingston-Rosanoff","year":"2019","journal-title":"J Am Coll Surg"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0031","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1097\/TP.0000000000000760","article-title":"Cancer-specific and all-cause mortality in kidney transplant recipients with and without previous cancer","volume":"99","author":"Viecelli","year":"2015","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.semnephrol.2022.01.003_bib0032","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/TP.0b013e3182637078","article-title":"Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable?","volume":"94","author":"Batabyal","year":"2012","journal-title":"Transplantation"},{"issue":"1-2","key":"10.1016\/j.semnephrol.2022.01.003_bib0033","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0041-1345(00)02698-1","article-title":"Recurrence of cancer after renal transplantation","volume":"33","author":"Chapman","year":"2001","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0034","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/ajt.16318","article-title":"Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0035","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ajt.16324","article-title":"Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: a consensus expert opinion statement","volume":"21","author":"Al-Adra","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0036","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ajt.16366","article-title":"Balancing uncertain risks in candidates for solid organ transplantation with a history of malignancy: who is safe to transplant?","volume":"21","author":"Hart","year":"2021","journal-title":"Am J Transplant"},{"issue":"6871","key":"10.1016\/j.semnephrol.2022.01.003_bib0037","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van 't Veer","year":"2002","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0038","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s10549-013-2831-4","article-title":"Long-term impact of the 70-gene signature on breast cancer outcome","volume":"143","author":"Drukker","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.semnephrol.2022.01.003_bib0039","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0040","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ajt.14003","article-title":"The novel application of genomic profiling assays to shorten inactive status for potential kidney transplant recipients with breast cancer","volume":"17","author":"Mukhtar","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/487285","article-title":"Multiple myeloma and kidney disease","volume":"2013","author":"Katagiri","year":"2013","journal-title":"ScientificWorldJournal"},{"issue":"10","key":"10.1016\/j.semnephrol.2022.01.003_bib0042","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1503\/cmaj.1041588","article-title":"Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation","volume":"173","author":"Knoll","year":"2005","journal-title":"CMAJ"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0043","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/nep.12068","article-title":"KHA-CARI guideline: recipient assessment for transplantation","volume":"18","author":"Campbell","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0044","article-title":"Kidney transplantation in patients with multiple myeloma: narrative analysis and review of the last 2 decades","author":"Chitty","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0045","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0046","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.transproceed.2018.10.005","article-title":"Kidney transplantation after hematopoietic cell transplantation in plasma cell dyscrasias: case reports","volume":"51","author":"Dom\u00ednguez-Pimentel","year":"2019","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0047","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/ajt.14731","article-title":"Plasma cell diseases and organ transplant: a comprehensive review","volume":"18","author":"Cowan","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0048","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10157-018-1672-1","article-title":"Kidney transplantation for treatment of end-stage kidney disease after haematopoietic stem cell transplantation: case series and literature review","volume":"23","author":"Tsuchimoto","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0049","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa074191","article-title":"Tolerance and chimerism after renal and hematopoietic-cell transplantation","volume":"358","author":"Scandling","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0050","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0051","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ajt.14970","article-title":"Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor-a multicenter analysis","volume":"19","author":"Eder","year":"2019","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0052","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/ajt.13978","article-title":"Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines","volume":"17","author":"Acuna","year":"2017","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0053","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1681\/ASN.2018121232","article-title":"One-time fecal immunochemical screening for advanced colorectal neoplasia in patients with CKD (DETECT Study)","volume":"30","author":"Wong","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0054","doi-asserted-by":"crossref","first-page":"e4657","DOI":"10.1136\/bmj.e4657","article-title":"Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy","volume":"345","author":"Collins","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1445-2197.2002.02352.x","article-title":"Increased incidence of benign breast disease in female renal transplant patients receiving cyclosporin","volume":"72","author":"Sangthawan","year":"2002","journal-title":"ANZ J Surg"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0056","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1111\/ajt.14272","article-title":"Uptake of cancer screening tests among recipients of solid organ transplantation","volume":"17","author":"Acuna","year":"2017","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0057","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2215\/CJN.05990616","article-title":"Patterns and predictors of screening for breast and cervical cancer in women with CKD","volume":"12","author":"Wong","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0058","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1440-1797.2011.01549.x","article-title":"Knowledge, beliefs and attitudes of kidney transplant recipients regarding their risk of cancer","volume":"17","author":"Williams","year":"2012","journal-title":"Nephrology (Carlton)"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0059","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2215\/CJN.10090916","article-title":"Beliefs and attitudes to bowel cancer screening in patients with CKD: a semistructured interview study","volume":"12","author":"James","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0060","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008163","article-title":"Eliciting patient preferences, priorities and trade-offs for outcomes following kidney transplantation: a pilot best-worst scaling survey","volume":"6","author":"Howell","year":"2016","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.semnephrol.2022.01.003_bib0061","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.semnephrol.2022.01.003_bib0062","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0063","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaad.2017.11.042","article-title":"Hydrochlorothiazide use and risk of nonmelanoma skin cancer: a nationwide case-control study from Denmark","volume":"78","author":"Pedersen","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0064","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.2215\/CJN.02560220","article-title":"Association between use of hydrochlorothiazide and risk of keratinocyte cancers in kidney transplant recipients","volume":"15","author":"Letellier","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/ajt.13596","article-title":"Immunosuppressive medications and squamous cell skin carcinoma: nested case-control study within the skin cancer after organ transplant (SCOT) cohort","volume":"16","author":"Coghill","year":"2016","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0066","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1600-6143.2011.03751.x","article-title":"Reversal of UVA skin photosensitivity and DNA damage in kidney transplant recipients by replacing azathioprine","volume":"12","author":"Hofbauer","year":"2012","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0067","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1111\/ajt.13863","article-title":"Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis","volume":"16","author":"Jiyad","year":"2016","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0068","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"Euvrard","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0069","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2015.5548","article-title":"Association of sirolimus use with risk for skin cancer in a mixed-organ cohort of solid-organ transplant recipients with a history of cancer","volume":"152","author":"Karia","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0070","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.kint.2016.11.008","article-title":"The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine","volume":"91","author":"Lim","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4369574","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J Transplant"},{"issue":"8","key":"10.1016\/j.semnephrol.2022.01.003_bib0072","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0073","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0074","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.semnephrol.2022.01.003_bib0075","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/ajt.12852","article-title":"Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis","volume":"14","author":"Murakami","year":"2014","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0076","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2016.11.024","article-title":"Acute kidney allograft rejection precipitated by lenalidomide treatment for multiple myeloma","volume":"69","author":"Lum","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0077","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.transproceed.2018.01.014","article-title":"Severe renal allograft rejection resulting from lenalidomide therapy for multiple myeloma: case report","volume":"50","author":"Walavalkar","year":"2018","journal-title":"Transplant Proc"},{"issue":"10","key":"10.1016\/j.semnephrol.2022.01.003_bib0078","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/ajt.12391","article-title":"Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis","volume":"13","author":"Meyers","year":"2013","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0079","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/BF02550087","article-title":"Interferon alpha therapy for chronic active hepatitis type C after renal transplantation and allograft rejection","volume":"27","author":"Takahara","year":"1995","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0080","first-page":"529","article-title":"A case of allograft rejection induced by the interferon-alpha therapy to hepatitis type C after renal transplantation","volume":"40","author":"Kakimoto","year":"1994","journal-title":"Hinyokika Kiyo"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0081","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/ndt\/gfm678","article-title":"Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts","volume":"23","author":"W\u00e9clawiack","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"19","key":"10.1016\/j.semnephrol.2022.01.003_bib0082","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0083","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0084","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d'Izarny-Gargas","year":"2020","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0085","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0086","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.semnephrol.2022.01.003_bib0087","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene cloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0088","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt.1674","article-title":"CAR T-cell therapy in hematologic malignancies: a voyage in progress","volume":"107","author":"Holstein","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"10.1016\/j.semnephrol.2022.01.003_bib0089","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib0091","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0092","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0093","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"issue":"18","key":"10.1016\/j.semnephrol.2022.01.003_bib0094","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety and efficacy of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41409-020-01145-1","article-title":"Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease-a single center case series","volume":"56","author":"Luttwak","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0096","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0097","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1600-6143.2011.03896.x","article-title":"Epidemiology of posttransplant lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the French registry and analysis of subgroups of lymphomas","volume":"12","author":"Caillard","year":"2012","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib0098","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/j.1600-6143.2011.03544.x","article-title":"Post-transplant lymphoproliferative disorders: determination of donor\/recipient origin in a large cohort of kidney recipients","volume":"11","author":"Olagne","year":"2011","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0099","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/TP.0000000000002146","article-title":"The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience","volume":"102","author":"Peters","year":"2018","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.semnephrol.2022.01.003_bib0100","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.tp.0000219817.18049.36","article-title":"Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients","volume":"81","author":"Opelz","year":"2006","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0101","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(\u2605)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0102","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2022.01.003_bib0103","first-page":"427","article-title":"Adoptive T-cell immunotherapy","volume":"391","author":"Gottschalk","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0104","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13133","article-title":"Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children","volume":"22","author":"Chiou","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib0106","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/ajcp\/aqw216","article-title":"B-cell and classical Hodgkin lymphomas associated with immunodeficiency: 2015 SH\/EAHP Workshop report-part 2","volume":"147","author":"de Jong","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"10.1016\/j.semnephrol.2022.01.003_bib0107","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.24834","article-title":"Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report","volume":"116","author":"Cavaliere","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.semnephrol.2022.01.003_bib0108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2020.09.012","article-title":"Advancing palliative care in patients with CKD: from ideas to practice","volume":"77","author":"Chiu","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"10.1016\/j.semnephrol.2022.01.003_bib0109","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/jama.2020.14205","article-title":"Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness: a systematic review and meta-analysis","volume":"324","author":"Quinn","year":"2020","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.semnephrol.2022.01.003_bib0110","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/ajt.14522","article-title":"Palliative and end of life care in solid organ transplantation","volume":"17","author":"Wentlandt","year":"2017","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2022.01.003_bib0111","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1681\/ASN.2020030342","article-title":"End-of-life care among US adults with ESKD who were waitlisted or received a kidney transplant, 2005-2014","volume":"31","author":"Butler","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib0112","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/jpm.2019.0222","article-title":"Lung transplant pulmonologists' views of specialty palliative care for lung transplant recipients","volume":"23","author":"Nolley","year":"2020","journal-title":"J Palliat Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2022.01.003_bib113","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-6143.2012.04294.x","article-title":"Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study","volume":"13","author":"Tessari","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2022.01.003_bib114","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/ijc.27765","article-title":"Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008--a Swedish population-based study","volume":"132","author":"Krynitz","year":"2013","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.semnephrol.2022.01.003_bib115","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2022.01.003_bib116","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1681\/ASN.2015040373","article-title":"Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals","volume":"27","author":"Yanik","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.semnephrol.2022.01.003_bib117","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1111\/j.1600-6143.2012.04209.x","article-title":"Malignancies after kidney transplantation: Hong Kong renal registry","volume":"12","author":"Cheung","year":"2012","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2022.01.003_bib118","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ndt\/gfr277","article-title":"Malignancies after renal transplantation in Taiwan: a nationwide population-based study","volume":"27","author":"Li","year":"2012","journal-title":"Nephrol Dial Transplant"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929522000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929522000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:39:12Z","timestamp":1759448352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929522000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0270929522000031"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2022.01.003","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Concepts in Managing Malignancy in Kidney Transplant Patients","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2022.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}